Marc Frahm

just your latest thoughts as you've gotten into designing the phase three, just kind of how to address the potential differences for nine eighty nine

do you need to see kind of convincing monotherapy activity that if that was all you had would have justified moving forward

would you expect to be able to talk about kinda next steps and whether you think there is a pivotal path forward yet

Can you remind us just how antibiotic use is being treated? What's treated in Phase 2? And how that may or may not differ in the Phase 3 trial?